About this trial
To determine the efficacy of citicoline in improving cerebral blood flow parameters and neurological status among neonates with hypoxic-ischemic encephalopathy using Doppler resistive index and Sarnat-Sarnat score after 72 hours of therapy.
Eligibility criteria
Qualifiers
All inborn neonates diagnosed with APGAR score (Table 2) less then 8/10 at 5 min of life presenting to the emergency room within the first day of life.
Outborn babies admitted in the last 24 hours with history or clinical features of perinatal asphyxia.
Disqualifiers
Neonates who have received therapeutic hypothermia
Neonates with congenital, developmental or chromosomal malformations
Significant antenatal risk factors leading to early-onset sepsis\DIC or CNS depression unrelated to asphyxia
Preterm neonates <35 weeks
Trial design
Treatments tested in this trial
- Citicoline
- Standard medical treatment
Treatment groups
Sponsors and collaborators
Khyber Girls Medical College
Lead sponsor
Hayatabad Medical Complex
Collaborator